GT-929

N/A

Report date: 2024/11/01 16:14:26
NME

Base Information

Drug NameGT-929
Drug Alias NameGT-929
ClassificationSmall molecules > Molecular Glue
Mechanisms of ActionZinc finger protein Aiolos degradersDNA-binding protein Ikaros degraders
TargetsZinc finger protein AiolosDNA-binding protein Ikaros
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGluetacs Therapeutics (Shanghai) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGluetacs Therapeutics (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A